VEGFA and osteosarcoma: The anticancer activity of miR‐381 in osteosarcoma was validated by Tsai et al.,69 who showed that miR‐381 suppresses angiogenesis by targeting vascular endothelial growth factor‐A (VEGF‐A) and subsequently inhibiting the migration of endothelial progenitor cells (EPCs) as well as tube formation.